Quantcast

Latest Panitumumab Stories

2009-05-15 08:29:00

New Vectibix(R) (Panitumumab) Combination Chemotherapy Data New Data Reinforce Importance of Infection Prevention in Chemotherapy Patients Oncology Pipeline Continues to Advance With New Data in Multiple Tumor Types THOUSAND OAKS, Calif., May 15 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced it will present new data from the Company's oncology portfolio of approved and investigational cancer products at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting...

2009-04-24 09:30:00

Pivotal Trial Expected to Initiate in 2010 for Blinatumomab NEW YORK, April 24 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today held an R&D Day for investors and financial analysts at The Yale Club of New York City. The presentations highlighted significant areas of development across Micromet's BiTE antibody platform and included...

2009-04-22 06:00:00

Study Presented at 2009 AACR Meeting Highlights Potential Therapeutic Approach to Treat Patients Unresponsive to Erbitux and Vectibix DENVER, April 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, yesterday presented non-clinical data at the annual meeting of the American Association for Cancer Research (AACR). These non-clinical data indicate...

2009-04-16 08:34:00

Early Research Suggests that Understanding the Fundamental Mechanism of Angiogenesis is More Complicated Than Understanding the Function of VEGF - A Amgen Launches Angiogenesis Website THOUSAND OAKS, Calif., April 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that results from several preclinical studies investigating potential new cancer agents will be presented at the 2009 American Association for Cancer Research (AACR) Annual Meeting in Denver between April 18-22,...

2009-03-24 07:30:00

SAN JOSE, Calif., March 24 /PRNewswire/ -- Patent 7,507,704 issued on 03/24/09 to NexGen Biomedical, Inc. founder Mark Zamoyski of San Jose, California discloses an improved method of treating lung, brain, pancreatic, breast and colon cancers that are driven by a mutation known as HER1 overexpression (also called EGFR or c-ErbB-1). The patent presents a case for why today's concurrent HER1 blocker / S-Phase cytotoxic protocols achieve only a fraction of the potential inherent in the...

2009-03-16 06:00:00

BETHESDA, Md., March 16 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the publication of six abstracts for poster presentations at the 100th annual meeting of AACR taking place from April 20-24, 2009, in Denver, Colorado. The following posters will be presented: Lutterbuese, R. et al. (2009). Highly efficient lysis of KRAS- and...

2009-03-13 10:00:00

MISSISSAUGA, ON, March 13 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today reported that its poster entitled, "Binding properties of the anti-EGFR monoclonal antibody, nimotuzumab, limit interaction with the EGFR in renal and epidermal cells", has been accepted for presentation at the American Association for Cancer Research's (AACR)...

2009-01-17 10:17:00

With a pre-emptive, prophylactic skin regimen, patients who receive panitumumab for treatment of metastatic colorectal cancer may be able to avoid some of the skin-associated toxicities, according to data presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.Edith Mitchell, M.D., a clinical professor in the Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, presented data from the study, which...

2009-01-15 16:53:26

Large numbers of patients with advanced colon cancer should not get some of the most advanced drug treatments, a medical society study recommends. Patients whose tumors have certain mutations in a gene called KRAS should not receive drugs that include Erbitux, co-marketed in the United States by Eli Lilly & Co. and Bristol-Myers Squibb Co., the American Society of Clinical Oncology study said. The society also cited Amgen Inc.'s Vectibix. KRAS provides instructions for making a protein...

2008-12-16 07:00:00

KRAS Biomarker Presents Potential to Personalize Colorectal Cancer Treatment Determining Who Can Benefit from Vectibix(R) THOUSAND OAKS, Calif., Dec. 16 /PRNewswire-FirstCall/ --Amgen (Nasdaq: AMGN) today announced they will discuss the clinical utility of the KRAS gene as a predictive biomarker in patients with metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (EGFr) antibody Vectibix(R) (panitumumab) with the U.S. Food and Drug Administration's (FDA)...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related